Oridonin from Rabdosia rubescens: An emerging potential in cancer therapy – A comprehensive review
Cancer incidences are rising each year. In 2020, approximately 20 million new cancer cases
and 10 million cancer‐related deaths were recorded. The World Health Organization (WHO) …
and 10 million cancer‐related deaths were recorded. The World Health Organization (WHO) …
Tumor protein D52 (isoform 3) induces NF-κB–STAT3 mediated EMT driving neuroendocrine differentiation of prostate cancer cells
KK Sruthi, S Natani, R Ummanni - … Journal of Biochemistry & Cell Biology, 2024 - Elsevier
In prostate cancer (PCa) patients, a proto-oncogene Tumor protein D52 (TPD52) is
overexpressed, and it is involved in different cellular functions. In this study, we report that …
overexpressed, and it is involved in different cellular functions. In this study, we report that …
Cross talk of tumor protein D52 (TPD52) with KLF9, PKCε, and MicroRNA 223 in ovarian cancer
Background Gynecologic cancers comprise malignancies in the female reproductive organs.
Ovarian cancer ranks sixth in terms of incidence rates while seventh in terms of mortality …
Ovarian cancer ranks sixth in terms of incidence rates while seventh in terms of mortality …
TIAM1 signaling drives prostatic budding and branching phenotypes and is a potential therapeutic target for BPH
H Khedmatgozar, S Dutta, M Dominguez, D Latour… - bioRxiv, 2024 - biorxiv.org
Benign prostatic hyperplasia (BPH) is the most prevalent urologic disease in men aged over
50 years. However, the molecular mechanisms that drive BPH pathophysiology remain …
50 years. However, the molecular mechanisms that drive BPH pathophysiology remain …